Mounjaro is tirzepatide approved for type 2 diabetes. Here is who can get it, through which doors, and why weight-loss seekers usually want Zepbound instead.
To get Mounjaro, you need a prescription from a licensed provider, and the practical path depends on why you want it. With a type 2 diabetes diagnosis, the route is straightforward: your physician or a telehealth provider prescribes on-label, and insurance frequently covers it. For weight loss without diabetes, Mounjaro is off-label — legal to prescribe but rarely covered — and most people are better served asking for Zepbound, the same molecule approved specifically for weight management.
Both drugs are tirzepatide, a once-weekly injection with progressive dose titration, and the strongest trial results in the approved GLP-1 class: up to roughly 20.9 percent average weight loss over 72 weeks in SURMOUNT-1. Understanding the two-brand structure is the key to getting access right, because the doors that open — insurance, direct-from-manufacturer pricing, telehealth — differ by which label you pursue.
Eli Lilly sells tirzepatide under two names. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management — for adults with a BMI of 30 or higher, or 27 with a weight-related condition — and for obstructive sleep apnea in adults with obesity. Same active molecule, different labels, different coverage logic.
This matters because access follows the label. If you have T2D, ask for Mounjaro: it is on-label, insurers have clear policies, and endocrinologists prescribe it daily. If your goal is weight loss, the cleaner request is Zepbound — a provider does not have to reach off-label, prior authorization criteria are designed for your case, and Lilly's direct pharmacy program applies. The full Zepbound path has its own guide; the rest of this page covers both branches.
With a T2D diagnosis, three doors are open. First, your existing physician or endocrinologist — the standard route, and the right one if your diabetes care already lives there. Second, telehealth: platforms with providers licensed in your state can evaluate your history, labs included, and prescribe within 24 to 72 hours. Third, any retail or mail pharmacy fills the prescription once written.
Insurance behaves best on this branch. Mounjaro for T2D is commonly covered, with copays in the $25 to $50 range on covering plans, though prior authorization asking for your diagnosis and sometimes prior metformin use is routine. List price without coverage is about $1,069 per month, which is why confirming your formulary status before the first fill is worth the phone call.
Timing expectations for this branch: with labs already on file, a telehealth T2D evaluation and prescription can complete inside three days, while a first appointment with a new endocrinologist may sit weeks out. Pharmacy stock is no longer the constraint it was during the shortage years — the FDA declared the tirzepatide shortage resolved in December 2024 — so once prior authorization clears, most retail pharmacies fill within a day or two. If yours lacks your dose, ask the prescriber to route the script to a mail pharmacy rather than waiting on a restock.
Free online assessment · licensed providers · plans from $199/mo
Providers can legally prescribe Mounjaro off-label for weight management, and some do. But in 2026 this path is mostly friction: insurers almost never cover Mounjaro without a T2D diagnosis, the $1,069 list price applies at the counter, and Lilly's self-pay vial program is attached to Zepbound, not Mounjaro.
The result is a simple decision rule. If you do not have type 2 diabetes and your goal is weight loss, request Zepbound — clinically equivalent molecule, on-label indication, and access to LillyDirect single-dose vials at $349 per month for 2.5 mg and $499 for 5 mg and above with timely refills. The off-label Mounjaro route survives mainly for edge cases: patients whose plan documents happen to treat it favorably, or continuity for people who started on it during earlier shortage-era availability.
Numbers you should know before choosing a door. Mounjaro lists around $1,069 per month; covered T2D patients typically pay far less after prior authorization. Zepbound lists around $1,086, but LillyDirect self-pay vials bring cash cost to $349 to $499 per month. Compounded tirzepatide through licensed telehealth runs roughly $199 to $449 per month — with the post-shortage caveat that the FDA declared the tirzepatide shortage resolved in December 2024, so compounded access requires a personalized prescription rather than a mass-produced copy.
HSA and FSA funds can be applied to any of these prescribed routes. The pattern to notice: for weight loss, every affordable channel — manufacturer vials, compounded programs, covered prior authorizations — runs through the weight-management label or a personalized prescription, not through off-label Mounjaro at list price. Cash-pay strategy across the whole GLP-1 class is consolidated in the no-insurance playbook.
If you have type 2 diabetes: book your physician or a telehealth visit, bring recent labs, ask for Mounjaro on-label, and let the office run prior authorization. Expect a decision within days to two weeks and a pharmacy fill immediately after.
If you are seeking weight loss without T2D: skip the off-label detour. Confirm you meet the criteria — BMI 30, or 27 with a condition like hypertension or sleep apnea — using the eligibility assessment, then pursue Zepbound through telehealth or your doctor, with LillyDirect vials as the self-pay backstop. If tirzepatide pricing is still out of range, compounded tirzepatide programs from $199 per month through licensed telehealth are the lower-cost legitimate alternative. Either way, the once-weekly routine and titration schedule are identical — what differs is purely which door you walk through.
Free online assessment · licensed providers · plans from $199/mo
How to Get Mounjaro in 2026
Take a free online assessment with a licensed provider — approval in minutes, medication delivered to your door.
Find My GLP-1 Pen